ProFactor Pharma (PFP) secures License Agreement with major Biotech company
Agreement with Indian Biotech company will allow further development and commercialisation of game-changing low cost Recombinant FVIII
Profactor Pharma have announced the successful execution of a Development and Commercialization Licensing Agreement with one of India’s foremost biotechnology companies to further develop, manufacture and commercialise PFP’s low-cost Factor VIII recombinant protein (PFP’s lead asset) for the treatment of haemophilia A.
As part of the Licensing Agreement, the Indian partner will scale PFP’s technology, conduct clinical trials and commercialize the recombinant FVIII protein in India and a number of other territories globally. The Licensing Agreement involves milestone- and royalty-on-sales based downstream payments for PFP.
Haemophilia A is a genetic disorder where the Factor VIII gene is defective, meaning the patient does not make enough, or any, Factor VIII to stop bleeding. Research from the World Federation of Haemophilia suggests the disorder affects 1 in 5,800 males and that there are more than 660,000 Haemophilia A patients worldwide, but only around 220,000 are currently treated. Most of these under treated patients live in Low-Middle Income countries, where the prices of these treatments, if available at all, are too high to be affordable for most patients.
With support from investors Kelvin Capital Ltd and Scottish Enterprise, PFP has developed a patent-protected CHO cell line with exceptionally high yields of recombinant human Factor VIII (rhFVIII; moroctocog alfa), combined with a proprietary manufacturing process that further maximises production efficiency.
The out-licensing of the development and commercialization of its lead asset will allow PFP to focus on advancing the second product in its pipeline, an innovative, enhanced-half-life rhFVIII. Following the completion of the ongoing preclinical Proof-of-Concept study, expected early 2026, PFP plans to initiate a Series A fundraise to support this product’s continued development toward and into clinical trials.
Jaymin Amin, CEO of ProFactor Pharma, said: “We are delighted that the development of our high-yielding cell line and manufacturing process has led to a collaboration with a reputable and highly experienced biotechnology company. This agreement brings us closer to fulfilling our mission to make recombinant Factor VIII (FVIII) affordable and accessible for underserved populations worldwide.”
Malcolm Weir, Chairman of the Board of Directors of ProFactor Pharma, said: “This licensing agreement has the potential to be a real game changer for the treatment of Haemophilia A, especially in underserved markets across the world, including a large Haemophilia population in India, that cannot afford to buy current treatments”
Angus Hay, Director of Kelvin Capital, said: “This licensing agreement is a major validation of ProFactor Pharma’s science, team and long-term vision. From the outset, the company has been focused on solving a critical global health challenge by dramatically reducing the cost of recombinant Factor VIII. Seeing that innovation translate into a commercial partnership with the potential for real patient impact in underserved markets is exactly the outcome we look to support as investors.”
